Q-omics provides the consensus-scored INSL3 profile across patient tissues and cancer cell-line models. INSL3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, INSL3 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, INSL3 RNA expression shows 14,515 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, THCA, and ESCA as cancer lineages where INSL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INSL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INSL3 survival associations across molecular data types. INSL3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INSL3 RNA expression–survival associations across cancer types. High INSL3 expression shows unfavorable associations in KIRC and LUAD, but favorable associations in BLCA, CESC, SKCM and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for INSL3 RNA expression.
This table summarizes INSL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for INSL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INSL3 shows lower tumor expression in KICH and BRCA and higher tumor expression in THCA, LUAD, KIRC and KIRP. The THCA box plot shows higher INSL3 RNA expression in tumor versus normal tissue (log2 FC = +1.100, t-test p < 0.001).
This table shows molecular features associated with INSL3 in patient tissues and cancer cell lines. In patient samples, INSL3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, INSL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
